T1	total-participants 610 615	1,009
T3	intervention-participants 657 660	336
T4	control 663 678	XRT and placebo
T5	control-participants 684 687	336
T7	intervention-participants 710 713	337
T11	cv-bin-percent 1022 1025	49%
T13	iv-bin-percent 1098 1101	63%
T14	outcome 1201 1233	reduction in hazard rate of IBTR
T15	iv-bin-percent 1197 1200	81%
T17	iv-bin-percent 1284 1289	16.5%
T18	cv-bin-percent 1300 1304	9.3%
T19	iv-bin-percent 1331 1335	2.8%
T24	condition 56 91	ipsilateral breast tumor recurrence
T25	eligibility 112 172	women with invasive breast cancers of one centimeter or less
T26	outcome 1748 1756	Survival
T27	iv-bin-percent 1781 1784	93%
T28	cv-bin-percent 1786 1789	94%
T29	iv-bin-percent 1795 1798	93%
T6	outcome 1032 1051	hazard rate of IBTR
T2	outcome 1235 1263	Cumulative incidence of IBTR
T12	outcome 1457 1483	Distant treatment failures
T16	outcome 1661 1677	reduction in CBC
T20	intervention 0 37	Tamoxifen, radiation therapy, or both
T8	outcome-Measure 716 729	Rates of IBTR
T9	outcome-Measure 731 749	distant recurrence
T10	outcome-Measure 755 788	contralateral breast cancer (CBC)
